Teladoc Health, Inc. (TDOC) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Teladoc Health, Inc. (TDOC) stock forecast summary
On Oct. 14, 2026, TDOC is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Teladoc Health, Inc. is a small-cap company with a market capitalization of $1.09B. It ranks number 1 by market capitalization among the 5 Services-Offices & Clinics of Doctors of Medicine issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for TDOC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, TDOC included.
Follow TDOC freeTDOC price chart and AI forecast
How TDOC ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Teladoc Health, Inc. (TDOC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Offices & Clinics of Doctors of Medicine peers listed below that report each metric.
Valuation & Market
| Metric | TDOC | Rank |
|---|---|---|
| Market Cap | $1.09B | 1/5 |
| P/B Ratio | 0.83x | – |
| EPS | $-1.16 | – |
| Book Value/Share | $7.21 | – |
| Revenue/Share | $13.70 | – |
| FCF/Share | $1.40 | – |
Profitability & Margins
| Metric | TDOC | Rank |
|---|---|---|
| ROE | -13.5% | 4/6 |
| ROA | -6.4% | 5/8 |
| ROIC | -13.6% | 5/8 |
| Gross Margin | 69.0% | 3/6 |
| Operating Margin | -7.5% | 5/8 |
| Net Margin | -7.1% | 6/8 |
| EBT Margin | -7.3% | 4/8 |
| Tax Rate | 2.9% | – |
Financial Health
| Metric | TDOC | Rank |
|---|---|---|
| Current Ratio | 0.83x | 6/8 |
| Quick Ratio | 0.81x | 5/6 |
| D/E Ratio | 1.11x | 4/6 |
| Financial Leverage | 2.11x | 4/6 |
| Interest Coverage | -20.9x | 5/8 |
| Working Capital | -$233M | 8/8 |
Cash Flow
| Metric | TDOC | Rank |
|---|---|---|
| Operating Cash Flow | $261M | 2/8 |
| Free Cash Flow | $254M | 1/6 |
| Capital Spending | -$7M | 5/6 |
| OCF Growth YoY | -13.9% | 3/5 |
| FCF Growth YoY | -13.0% | – |
| FCF/Sales | 10.2% | 2/6 |
| CapEx/Sales | 0.3% | 6/6 |
Operational Efficiency
| Metric | TDOC | Rank |
|---|---|---|
| Asset Turnover | 0.90x | 3/7 |
| Receivables Turnover | 11.3x | – |
| Inventory Turnover | 26.8x | – |
| Fixed Assets Turnover | 100.8x | 1/6 |
| Days Sales Outstanding | 32 days | – |
| Days Inventory | 14 days | – |
| Payables Period | 18 days | 5/5 |
| Cash Conversion Cycle | 28 days | – |
Income Statement
| Metric | TDOC | Rank |
|---|---|---|
| Total Revenue | $2.49B | 2/7 |
| Operating Income | -$186M | 8/8 |
| Net Income | -$177M | 8/8 |
| R&D Expense | $270M | – |
| SG&A Expense | $614M | 1/7 |
| Cost of Goods Sold | $773M | 2/6 |
Dividend & Shareholder Information
| Metric | TDOC | Rank |
|---|---|---|
| Shares Outstanding | 182M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.15B | 41.6% of assets |
| Cash & Short-term Investments | $774M | 28.1% of assets |
| Accounts Receivable | $221M | 8.0% of assets |
| Inventory | $29M | 1.0% of assets |
| Total Liabilities | $1.45B | 52.5% of assets |
| Short-term Debt | $1.34B | 48.7% of assets |
TDOC quarterly financials and insider trading
Teladoc Health, Inc. (TDOC) industry peers
Companies classified under the same SEC industry code as Teladoc Health, Inc. (Services-Offices & Clinics of Doctors of Medicine): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| TDOC Teladoc Health, Inc. | ▶ | $1.09B |
| SBC Sbc Medical Group Holdings Inc | ▼ | $547M |
| LFMD Lifemd, Inc. | ▲ | $119M |
| AIRS Airsculpt Technologies, Inc. | ▲ | $117M |
| HLYK Healthlynked Corp | ▲ | $6M |
| CDIX Cardiff Lexington Corp | ▼ | N/A |
| HIMS Hims & Hers Health, Inc. | ▶ | N/A |
| STLN Starling Oncology, Inc. | ▲ | N/A |
Where TDOC sits on the market map
Teladoc Health, Inc. (TDOC) stock news
Loading...
Teladoc Health, Inc. (TDOC) stock forecast FAQ
What is the Teladoc Health, Inc. (TDOC) stock forecast?
On Oct. 14, 2026, TDOC is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Teladoc Health, Inc. stock predictions?
A per-ticker accuracy statistic for TDOC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Teladoc Health, Inc. forecasts updated?
Teladoc Health, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Teladoc Health, Inc.'s industry peers?
8 issuers in our coverage, TDOC included, share the SEC industry code Services-Offices & Clinics of Doctors of Medicine. The largest are: Sbc Medical Group Holdings Inc (SBC), Lifemd, Inc. (LFMD), Airsculpt Technologies, Inc. (AIRS), Healthlynked Corp (HLYK), Cardiff Lexington Corp (CDIX), Hims & Hers Health, Inc. (HIMS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.